Loading...
•
Sep 30, 2021
Baxter Q3 2021 Earnings Report
Reported an increase in revenue and earnings per share driven by growth in BioPharma Solutions and Medication Delivery.
Key Takeaways
Baxter's Q3 2021 results showed a 9% increase in worldwide sales, reaching $3.2 billion. U.S. GAAP earnings per share increased by 29% to $0.89, and adjusted EPS increased by 23% to $1.02. The company has updated its full-year outlook, expecting sales growth of 7% to 8% and U.S. GAAP EPS of $2.82 to $2.86.
Third-quarter revenue increased 9% on a reported basis, reaching $3.2 billion.
U.S. GAAP earnings per share (EPS) increased 29% to $0.89; Adjusted EPS increased 23% to $1.02.
Baxter expects full-year 2021 sales growth of 7% to 8% on a reported basis.
Baxter now expects full-year U.S. GAAP EPS of $2.82 to $2.86 and adjusted EPS of $3.58 to $3.62.
Baxter
Baxter
Baxter Revenue by Segment
Baxter Revenue by Geographic Location
Revenue by Segment
Pharmaceuticals Revenue
CapyFin.comOther Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
For full-year 2021, Baxter now expects U.S. GAAP earnings of $2.82 to $2.86 per diluted share and adjusted earnings, before special items, of $3.58 to $3.62 per diluted share. The company expects sales growth of 7% to 8% on a reported basis, 5% to 6% on a constant currency basis and 4% to 5% on an operational basis.
Positive Outlook
- Sales growth of 3% to 4% on a reported basis
- Sales growth of 4% to 5% on a constant currency basis
- Sales growth of 3% to 4% on an operational basis
- U.S. GAAP earnings of $0.75 to $0.79 per diluted share
- Adjusted earnings, before special items, of $1.00 to $1.04 per diluted share
Revenue & Expenses
Visualization of income flow from segment revenue to net income